Pacira Biosciences, Inc. (Pacira Pharmaceuticals, Inc.) - 10-K Summary
Business Context and Reporting Period
Reporting Period: Fiscal year ended December 31, 2010.
Company Profile: Pacira is an emerging specialty pharmaceutical company focused on developing, commercializing, and manufacturing proprietary products based on its DepoFoam drug delivery technology for hospitals and ambulatory surgery centers.
Key Milestone: In September 2010, the Company filed a New Drug Application (NDA) with the FDA for its lead product candidate, EXPAREL (long-acting bupivacaine), which was accepted for review on December 10, 2010. The PDUFA goal date for a decision is July 28, 2011.
Current Portfolio: The Company manufactures two FDA-approved products for commercial partners: DepoCyt(e) (lymphomatous meningitis) and DepoDur (post-operative pain). It also holds preclinical candidates DepoNSAID and DepoMethotrexate.
Key Financial Metrics (Year Ended Dec 31, 2010)
| Metric | 2010 (in thousands) | 2009 (in thousands) |
|---|---|---|
| Total Revenues | $14,562 | $15,006 |
| Net Loss | $(27,149) | $(31,707) |
| Research & Development Expenses | $18,628 | $26,233 |
| Cash and Cash Equivalents (Dec 31, 2010) | $26,133 | $7,077 |
| Working Capital | $14,817 | $(1,868) |
| Long-Term Debt (Principal) | $26,250 | $0 |
| Accumulated Deficit | $(136,911) | $(109,762) |
Note: Gross margins on supply revenue were negative (-49%) in 2010 due to excess manufacturing capacity costs. Excluding excess capacity, the margin was 30%.
Material Changes vs. Prior Period
- Revenue: Decreased 3% to $14.6 million. This was driven by a $1.4 million decrease in collaborative licensing revenue (reduced contract work for Amylin) and a $0.3 million decrease in royalties, partially offset by a $1.3 million increase in supply revenue (higher DepoCyt(e) sales to European partners).
- Operating Expenses:
- R&D: Decreased 29% to $18.6 million, primarily due to a $6.7 million reduction in third-party clinical trial costs following the completion of pivotal Phase 3 studies for EXPAREL.
- Selling, General & Administrative (SG&A): Increased 20% to $6.0 million, driven by higher audit/tax filing costs and initial hiring of commercial personnel.
- Liquidity: Cash position improved significantly from $7.1 million to $26.1 million, bolstered by a new $26.25 million credit facility with Hercules Technology Growth Capital and proceeds from convertible notes.
- Debt Structure: The Company entered into a $26.25 million term loan (Hercules Credit Facility) in November 2010, replacing a previous GE Capital facility. Several prior secured and convertible notes were converted into common stock upon the Company's IPO in February 2011.
Guidance, Outlook, and Risks
Outlook & Strategy:
- The Company anticipates FDA approval for EXPAREL by the PDUFA goal date of July 28, 2011.
- Upon approval, Pacira plans to launch a dedicated sales force of approximately 60 representatives, expanding to 100 within three years.
- The Company expects to continue incurring significant losses as it prepares for commercialization and expands its infrastructure.
Capital Resources:
- Following an IPO in February 2011 (raising ~$42 million gross), management believes cash resources are sufficient to fund operations for at least 12 months.
- Long-term profitability depends on the successful commercialization of EXPAREL.
Key Risks & Contingencies:
- Regulatory Approval: Failure to obtain FDA approval for EXPAREL or delays in the review process would materially harm the business.
- Manufacturing: The Company is the sole manufacturer of DepoCyt(e) and DepoDur at two facilities in San Diego. Any disruption could breach supply agreements.
- Debt Covenants: The Hercules Credit Facility and a Royalty Interests Assignment Agreement with Paul Capital contain restrictive covenants. Default could lead to acceleration of debt or foreclosure on assets.
- Competition: EXPAREL faces competition from established opioids, generic bupivacaine, and other extended-release bupivacaine products in development.
Investor Verification Checklist
- EXPAREL NDA Status: Verify the FDA's decision timeline and any requests for additional data following the December 2010 acceptance.
- Manufacturing Capacity: Confirm the readiness of the renovated EXPAREL production line for FDA pre-approval inspection and commercial scale-up.
- Debt Obligations: Review the specific covenants in the Hercules Credit Facility and the Paul Capital royalty assignment agreement to understand triggers for default or repurchase obligations.
- Commercial Readiness: Assess the progress of hiring the sales force and establishing distribution channels for a potential 2011 launch.
- Revenue Sustainability: Monitor the stability of DepoCyt(e) and DepoDur supply and royalty revenues, which currently fund operations but are subject to partner sales performance.